Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Role of Pro-angiogenic Immune Cells in Human Pregnancies

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Hillel Yaffe Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT01177020
First received: May 12, 2010
Last updated: August 5, 2010
Last verified: August 2010
  Purpose

Identification of the presence of proangiogenic immune cells in normal human placentas may enable predication of some pregnancy disorders.


Condition Intervention
Fetal Growth Retardation
Preeclampsia
Other: Biological specimen

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • To find the angiogenic potential of proangiogenic immune cells derived from human placentas. [ Time Frame: Two years ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: August 2010
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Placentas after delivery or abortion Other: Biological specimen
Biological specimen taken from placenta

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Placentas after delivery or abortion

Criteria

Inclusion Criteria:

  • Placentas that have been delivered in the Medical Center

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01177020

Contacts
Contact: Elad Mei-Dan, MD 972-4-6304248 eladmei@yahoo.com

Locations
Israel
Hillel Yaffe Medical Center Recruiting
Hadera, Israel, 38100
Principal Investigator: Elad Meidan, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

No publications provided

Responsible Party: Elad Mei-Dan, MD, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01177020     History of Changes
Other Study ID Numbers: HYMC1069A
Study First Received: May 12, 2010
Last Updated: August 5, 2010
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Fetal Growth Retardation
Pre-Eclampsia
Fetal Diseases
Growth Disorders
Hypertension, Pregnancy-Induced
Pathologic Processes
Pregnancy Complications

ClinicalTrials.gov processed this record on November 20, 2014